Skip to main content

Upstream Bio, Inc.

UPB
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0002022626

In the last 90 days, Upstream Bio, Inc. insiders filed 0 open-market purchases and 5 sales; 148 institutions reported holding it in 13F filings for Q2 2026, worth $350.1M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 16, 2026
$117.8M
Insider buysOpen market, last 90 days
0
Insider sellsLast 90 days, $27.6K in total
5
13F holdersQ2 2026, +9 vs. previous quarter
148
13F valueReported value at the end of Q2 2026
$350.1M
Superinvestors holdingAt the end of Q2 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
$2.85M
+20.4% year over year
Net income, FY2025
-$143.4M
No comparable prior period
Free cash flow, FY2025
-$133.4M
No comparable prior period
Revenue, Q3 FY2026
$395.0K
−42.2% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2025: $143.4M (5026.0% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
3.55M
Shares sold short
Change
−930.6K
−20.8% vs. previous
Days to cover
2.70
At average daily volume

Superinvestors holding UPB, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding UPB at the end of Q2 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Upstream Bio, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 17, 2026 (view filing)4:05 PM ETSep 161 dayGray MichaelCFO and COOSSale−853$5.49−$4.68K−3.0%27.9K after
Sep 17, 2026 (view filing)4:05 PM ETSep 161 dayAmbrose AllisonGeneral CounselSSale−485$5.49−$2.66K−3.0%15.6K after
Sep 17, 2026 (view filing)4:05 PM ETSep 161 dayDeykin AaronChief Medical OfficerSSale−895$5.49−$4.91K−2.7%32.3K after
Sep 17, 2026 (view filing)4:05 PM ETSep 161 daySutherland Everett RandChief Executive OfficerSSale−2.10K$5.49−$11.5K−3.0%68.7K after
Sep 17, 2026 (view filing)4:05 PM ETSep 161 dayHoughton AdamChief Business OfficerSSale−700$5.49−$3.84K−3.0%22.9K after
Jun 17, 2026 (view filing)Jun 161 dayGray MichaelCFO and COOSSale−853$6.10−$5.20K−2.9%28.8K after
Jun 17, 2026 (view filing)Jun 161 daySutherland Everett RandChief Executive OfficerSSale−2.10K$6.10−$12.8K−2.9%70.8K after
Jun 17, 2026 (view filing)Jun 161 dayHoughton AdamChief Business OfficerSSale−700$6.10−$4.27K−2.9%23.6K after
Jun 17, 2026 (view filing)Jun 161 dayDeykin AaronChief Medical OfficerSSale−895$6.10−$5.46K−2.6%33.2K after
Jun 17, 2026 (view filing)Jun 161 dayAmbrose AllisonGeneral CounselSSale−477$6.10−$2.91K−2.9%16.0K after

Top 10 13F holders, Q2 2026

See all 148 holders

The largest institutional positions in Upstream Bio, Inc. at the end of Q2 2026; share changes are against Q1 2026.

Institutions holding UPB in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
FMR LLC8,162,897$56.5M0.00%+61,334+0.8%Added
OrbiMed Advisors LLC5,693,589$39.4M0.75%00.0%Unchanged
Norges Bank3,768,619$26.1M0.00%+3,768,619New
BlackRock, Inc.3,753,358$26.0M0.00%+382,669+11.4%Added
Decheng Capital LLC2,724,868$18.9M2.58%00.0%Unchanged
Enavate Sciences GP, LLC2,459,703$17.0M4.93%00.0%Unchanged
Vanguard Capital Management LLC1,876,734$13.0M0.00%+3,160+0.2%Added
Millennium Management LLC1,143,775$7.91M0.01%+206,452+22.0%Added
D. E. Shaw & Co., Inc.1,036,044$7.17M0.00%+215,564+26.3%Added
JPMorgan Chase & Co1,012,044$7.01M0.00%+549,043+118.6%Added

Holders of 5% or more of UPB

See all 3 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Upstream Bio, Inc..

Largest holders of UPB from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Norges Bank13G/A7.73%4.21M shares+2.43 ppfrom 5.30%Oct 24, 20252 filingsAug 12, 2026SEC
FMR LLC13G/A6.90%3.79M shares−7.90 ppfrom 14.80%Nov 7, 20244 filingsNov 6, 2026SEC
BlackRock, Inc.13G5.20%2.81M sharesNewJul 30, 20261 filingJul 30, 2026SEC